Results 31 to 40 of about 761 (100)

Competitive Binding of Ozanimod and Other Sphingosine 1-Phosphate Receptor Modulators at Receptor Subtypes 1 and 5

Frontiers in Pharmacology, 2022
Ozanimod, a sphingosine 1-phosphate (S1P) receptor modulator, binds with high affinity selectively to S1P receptor subtypes 1 (S1P1) and 5 (S1P5), and is approved in multiple countries for treating adults with relapsing forms of multiple sclerosis (MS ...
Julie V. Selkirk, Andrea Bortolato, Yingzhuo Grace Yan, Nathan Ching, Richard Hargreaves   +4 more
doaj   +1 more source

Data_Sheet_1_Repurposing the Sphingosine-1-Phosphate Receptor Modulator Etrasimod as an Antibacterial Agent Against Gram-Positive Bacteria.docx

, 2022
New classes of antibiotics are urgently needed in the fight against multidrug-resistant bacteria. Drug repurposing has emerged as an alternative approach to accelerate antimicrobial research and development.
Matej Zore (11106399), Paola San-Martin-Galindo (11024997), Adyary Fallarero (494453), Shella Gilbert-Girard (8748750), Kirsi Savijoki (1677550), Jayendra Z. Patel (640799), Leena Hanski (675511), Inés Reigada (11024994), Jari Yli-Kauhaluoma (276410)   +8 more
core   +1 more source

Low Incidence of Macular Edema and Other Ocular Events in the Etrasimod Development Program [PDF]

Journal of Crohn's and Colitis
Aoibhinn McDonnell, Alessandro Armuzzi, Marla Dubinsky   +2 more
exaly   +2 more sources

Efficacy and safety of etrasimod, a sphingosine 1-phosphate receptor modulator, in adults with moderate-to-severe atopic dermatitis (ADVISE)

, 2023
BACKGROUND: Etrasimod is an oral, selective, sphingosine 1-phosphate (S1P) receptor modulator in development for immune-mediated inflammatory disorders. Efficacy and safety of orally administered S1P receptor modulation in atopic dermatitis (AD) has not ...
Silverberg, Jonathan I, Andrew Selfridge, Ahluwalia, Gurpreet, Kris Liu, Selfridge, Andrew, Kircik, Leon, Robert Bissonnette, Guttman-Yassky, Emma, Leon Kircik, Murrell, Dedee F, Bissonnette, Robert, Jonathan I. Silverberg, Dedee F. Murrell, Gurpreet Ahluwalia, Liu, Kris, Emma Guttman‐Yassky   +15 more
core   +1 more source

The Effect of Etrasimod on Fecal Calprotectin and High-sensitivity C-reactive Protein: Results From the ELEVATE UC Clinical Program. [PDF]

Inflamm Bowel Dis
Biomarkers offer potential alternatives to endoscopies in monitoring ulcerative colitis (UC) progression and therapeutic response. This post hoc analysis of the ELEVATE UC clinical program assessed potential predictive values of fecal calprotectin (fCAL)
Jairath V, Jairath V, Rubin DT, Verstockt B, Çekin AH, Abreu MT, Lees CW, Fellmann M, Woolcott JC, Crosby C, Wu J, Bhattacharjee A, Herman D, Gu G, Siegmund B.   +14 more
europepmc   +2 more sources

Efficacy and Safety of Etrasimod in a Phase 2 Randomized Trial of Patients With Ulcerative Colitis

, 2020
BACKGROUND & AIMS: Etrasimod (APD334) is an oral, selective sphingosine 1-phosphate receptor modulator in development for immune-mediated inflammatory disorders.
Zhang, Jinkun, Naik, Snehal U., Vermeire, Severine, Sandborn, William J., Chiorean, Michael, Klassen, Preston, Panes, Julian, Cabell, Christopher H., Lee, Scott D., Peyrin-Biroulet, Laurent, Kuehbacher, Tanja, Yacyshyn, Bruce   +11 more
core   +1 more source

Efficacy and safety of the S1PR modulator etrasimod in the treatment of moderately to severely active ulcerative colitis during the induction phase: a systematic review and meta-analysis of randomized controlled trials

Frontiers in Pharmacology
BackgroundThe study aims to assess the efficacy and safety of the recently approved S1PR modulator etrasimod in adults with ulcerative colitis during the induction phase through meta-analysis.MethodsA systemic search was performed for randomized ...
Jingyue Qiu, Jiakuo Liu, Kexin Cai, Ting Xu, Wenwen Liu, Fei Lin, Fei Lin, Ning Shi   +7 more
doaj   +1 more source

Crystal Structures of Large-Volume Commercial Pharmaceuticals [PDF]

Structural Dynamics
As part of a continuing project, the room-temperature crystal structures of 17 commercial pharmaceutical APIs have been solved and refined using synchrotron X-ray powder diffraction data (11-BM at APS and Wiggler Low Energy Beamline at CLS), and ...
James A Kaduk, Anja Dosen, Thomas N Blanton   +2 more
doaj   +1 more source

Etrasimod intermediate [PDF]

The present study aims to identify and characterize the polymorphic form of the Etrasimod intermediate disclosed in international publication WO2011/094008 A1, specifically the compound of Formula (I)
Anonymous,
core   +1 more source

Targeting Cytokine Signaling and Lymphocyte Traffic via Small Molecules in Inflammatory Bowel Disease: JAK Inhibitors and S1PR Agonists

Frontiers in Pharmacology, 2019
The inflammatory Bowel diseases (IBDs) are a chronic, relapsing inflammatory diseases of the gastrointestinal tract with heterogeneous behavior and prognosis. The introduction of biological therapies including anti-TNF, anti-IL-12/23, and anti-integrins,
Tamara Pérez-Jeldres, Tamara Pérez-Jeldres, Tamara Pérez-Jeldres, Christopher J. Tyler, Christopher J. Tyler, Joshua D. Boyer, Joshua D. Boyer, Thangaraj Karuppuchamy, Thangaraj Karuppuchamy, Andrés Yarur, Daniel A. Giles, Shaila Yeasmin, Luke Lundborg, William J. Sandborn, Derek R. Patel, Jesús Rivera-Nieves, Jesús Rivera-Nieves   +16 more
doaj   +1 more source